ART Advanced Research Technologies Announces Q4 and FY 2008 Financial Results Conference Call
Published March 26th, 2009
ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, invites you to participate in a conference call to discuss the company’s financial results for the fourth quarter and year ended December 31, 2008. The conference call will follow the press release issued earlier on the same day, and will be held on:
Tuesday, March 31, 2009
5:00 p.m. (EST)
To participate in the conference call when dialing within the Montreal area, please dial (514) 861-1531, or (877) 667-7766 for the rest of North America. Outside of North America, please dial (514) 861-1531. Participants are asked to dial 10 minutes prior to the start time.
The conference call will feature Sebastien Gignac, President and Chief Executive Officer, and Jacques Bedard, Chief Financial Officer.
If you are unable to participate, a replay of the conference call will be available until April 14, 2009. To listen to the replay from the Montreal area, please dial (514) 861-2272, or, (800) 408-3053 for the rest of North America. From outside of North America, please dial (514) 861-2272. The access code for the replay is 2571417#.
We look forward to your participation and thank you for your interest in ART Advanced Research Technologies Inc.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART’s shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.
